Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics 與 TD2 合作開發用於治療晚期或轉移性實體瘤的 QN-302 的 1 期臨床開發
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.Â
專注於開發可能被指定爲孤兒藥的成人和兒科癌症的臨床階段治療公司Qualigen Therapeutics, Inc.（納斯達克股票代碼：QLGN）今天宣佈，它將與轉化藥物開發（TD2）合作，作爲合同研究組織（CRO）進行主要候選藥物 QN-302 的第一階段臨床開發。本月早些時候，Qualigen獲得了美國食品藥品管理局的IND許可，可以啓動一項針對治療晚期或轉移性實體瘤的小分子G-Qualplex（G4）選擇性轉錄抑制劑 QN-302 的1期臨床試驗。A
Tariq Arshad, M.D., M.B.A., Chief Medical Officer, stated: "I am delighted...
醫學博士、工商管理碩士、首席...
登入免費觀看全文
登入/註冊